New drug combo shows promise for Hard-to-Treat colorectal cancer
NCT ID NCT03712943
First seen Nov 14, 2025 · Last updated May 15, 2026 · Updated 19 times
Summary
This early-phase study tested the safety and best dose of combining two drugs, regorafenib and nivolumab, in 52 people with advanced colorectal cancer that had stopped responding to standard treatments. The goal was to see if this combination could help control the disease. Participants had a specific type of tumor (mismatch repair proficient) that typically does not respond well to immunotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.